###### Summary box

What is already known about this subject?
=========================================

-   The number of breast cancer survivors is growing due to improvements in early cancer detection and treatment.

-   The long-term risk of new primary malignancies among patients with breast cancer may be increased due to cancer treatment and/or shared risk factors.

What are the new findings?
==========================

-   The risk of being diagnosed with oesophagus cancer and stomach cancer was higher for patients diagnosed with breast cancer before 2007 than for the general population, while in later years the risk approximated unity.

-   The opposite was observed for colon cancer, where the risk was increased only after 2007.

-   The absolute cancer risks were relatively low.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Knowing and quantifying the risk of gastrointestinal cancers among patients with breast cancer are of major public interest to substantiate and possibly refine guideline recommendations.

-   The observed low absolute risks support that extensive screening strategies to detect more gastrointestinal cancers is not indicated among patients with breast cancer.

Background {#s1}
==========

Breast cancer is the most frequently diagnosed cancer among women in Western and Asian countries. It constitutes approximately one-third of all newly diagnosed tumours in women.[@R1] Because of the establishment of screening programmes for breast cancer with early detection and improvements in treatments, the mortality rates of breast cancer have decreased in most Western societies.[@R2]

Given the rise in prevalence of long-term survivors of breast cancer, concerns exist that the different treatment modalities have contributed to the development of new primary cancers. Endocrine therapy has been a cornerstone treatment in oestrogen receptor positive breast cancer and may interfere with several sites in the gastrointestinal tract with endocrine function. Radiotherapy may induce cancer in sites in close proximity to the breasts, that is, the pharynx, oesophagus, and gastric ventricle.[@R5]

Previous studies examined the risk of new primary gastrointestinal malignancies among patients with breast cancer.[@R5] Notwithstanding, studies were limited by follow-up periods (\<10 years),[@R5] lacked data on *human epidermal growth factor receptor 2* (*HER2*) status,[@R5] and few studies covered all types of gastrointestinal cancers.[@R10] Many studies also included patients with breast cancer diagnosed before 2007,[@R7] the year when tamoxifen was replaced by aromatase inhibitors in postmenopausal women with estrogen-receptor-positive breast cancer. Because the treatment of breast cancer has changed considerably over the past decades, and because some studies reported contradictory findings, it is necessary to revisit earlier findings. Such data are needed to guide follow-up programmes of these patients. Therefore, we performed a population-based cohort study of risks of new primary gastrointestinal cancers among patients with an incident breast cancer, compared with risks in the general population. We also evaluated whether the associations varied by time periods and treatment regimens.

Methods {#s2}
=======

Setting and design {#s2-1}
------------------

This nationwide population-based cohort study was conducted in Denmark, which has a population of 5.8 million inhabitants.[@R16] The national healthcare system is tax supported, ensuring unfettered access to general practitioners and hospitals for all Danish inhabitants, including care for patients with cancer.[@R17] Accurate linkage of all registries at the individual level is possible in Denmark owing to the unique central personal registry number assigned to each Danish inhabitant at birth and to residents on immigration.[@R17]

Patients with breast cancer {#s2-2}
---------------------------

All women≥18 years of age diagnosed with incident localised or regional spread breast cancer between 1 January 1990 and 31 December 2017 were identified using the Danish Cancer Registry (DCR).[@R18] The DCR contains detailed data, including cancer stage, on prospectively recorded incident cancers diagnosed in Denmark since 1943. All incident cases of cancer in Denmark have been reported to the DCR from all clinical departments and departments of pathology and forensic medicine. From 2004 onwards, reporting to the registry became electronic and administered by the Danish National Patient Registry (DNPR). Tumours have been classified according to the *International Classification of Diseases*, *Tenth Revision* and the *International Classification of Diseases for Oncology, Third Edition* since 1978. Routinely scheduled quality control is performed, ensuring a high degree of completeness and validity of the registry with 95%--98% completeness and accuracy of recorded diagnoses.[@R18]

We excluded patients with a history of cancer at any time before their hospital contact for breast cancer to ensure that cases of breast cancer and cancer outcomes both were incident. Data were retrieved on oestrogen receptor and *HER2* receptor status from the Patobank,[@R19] which is a nationwide Danish registry of all pathology specimens analysed since 1996. Data on breast cancer treatments were retrieved from DCR until end of 2003 and from the DNPR since 2004[@R20] (including radiotherapy, chemotherapy, tamoxifen therapy, aromatase inhibitor treatment, lumpectomy, and mastectomy). Data on lumpectomy and mastectomy were obtained from the DNPR and restricted to 1996 onwards due to data registration limitations.

Gastrointestinal cancers {#s2-3}
------------------------

We searched the DCR to identify any subsequent gastrointestinal cancer after the diagnosis of breast cancer. Gastrointestinal cancers included cancers of the oesophagus, stomach, small intestine, colon (including rectosigmoid colon), rectum, anal canal, liver, gallbladder and biliary tract, and pancreas. We also classified the cancers into upper gastrointestinal cancers (oesophagus, stomach, and small intestine), lower gastrointestinal cancers (colon, rectum, and anal), and other gastrointestinal cancers (liver, gallbladder and biliary tract, and pancreas). To avoid bias due to heightened diagnostic workup, we focused on 1-year breast cancer survivors in the main analysis and subgroup analyses. To examine potential temporal trends, we also stratified the main analysis by calendar time period (1990--2006 and 2007--2017). In this analysis, we restricted follow-up to 10 years. All codes used in the study are in [online supplementary tables 1 and 2](#SP1){ref-type="supplementary-material"}.
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Statistical analysis {#s2-4}
--------------------

The breast cancer cohort was characterised by median follow-up time, age group (18--49, 50--59, 60--69, ≥70 years), calendar year period of breast cancer diagnosis with cutpoints selected according to the 2007 introduction of aromatase inhibitors in Denmark (1990--2006 and 2007--2017),[@R21] oestrogen receptor and *HER2* receptor status, and breast cancer treatment within the first year after breast cancer diagnosis (radiotherapy, chemotherapy, tamoxifen therapy, aromatase inhibitor treatment, lumpectomy, and mastectomy). Additionally, patients were classified by Charlson Comorbidity Index scores (low, moderate, and severe comorbidity levels).[@R22] Cumulative gastrointestinal cancer incidences during 20 years of follow-up after breast cancer diagnosis were computed and graphically presented using the cumulative incidence risk function, accounting for death as a competing risk.[@R23] Incidence rates were calculated using the number of events divided by risk time. Associated 95% CIs were derived using a normal approximation (Wald interval),[@R25] assuming a Poisson distribution.

To contextualise the risk of new gastrointestinal cancers among patients with breast cancer with the cancer risk of the general population, we calculated standardised incidence ratios (SIRs) as the observed number of cancers relative to the expected number, based on national incidence rates by age in 5-year intervals, and by calendar period in 5-year intervals.[@R26] As the SIR estimates were calculated using indirect standardisation, they were not directly comparable to each other. Corresponding 95% CIs were derived using Byar's approximation, assuming that the observed number of cases in a specific category followed a Poisson distribution. We used exact 95% CIs when the observed number of cancers was less than ten.[@R27] Multiplying the number of person years of observation by national incidence rates yielded the number of cancer cases that would be expected if patients with breast cancer had the same risk of cancer as the general population. In SIR analyses, follow-up began 1 year after their hospital contact date for breast cancer, while follow-up ended at occurrence of a primary gastrointestinal cancer diagnosis, emigration, death, or 31 December 2017, whichever came first.

As a complement, we also evaluated the impact of different patient characteristics and treatment regimens during the first year following breast cancer on the subsequent risk of gastrointestinal cancers. To avoid conditioning on the future[@R28] and the risk of detection bias, follow-up was started 1 year after the breast cancer diagnosis (consistent with the main analysis), excluding patients with gastro-oesophageal cancer events or death within the first year. In these analyses, patient characteristics included breast cancer stage, oestrogen receptor and *HER2* receptor status, age groups, and treatment regimens included radiotherapy, chemotherapy, tamoxifen therapy, aromatase inhibitor treatment, lumpectomy, mastectomy. These subgroup analyses were performed for the main cancer groups only (ie, upper, lower, and other gastrointestinal cancers) to retain precise effect estimates.

To allow a minimum of 2 years of follow-up for all patients, we performed a sensitivity analysis, restricting the study population to 1 January 1990 and 31 December 2015.

Statistical analyses were performed using SAS, V.9.4 (SAS Institute). In Denmark, registry-based research does not require approval from an ethics committee or informed consent from patients.

Results {#s3}
=======

The cohort comprised 84 972 patients with a first-time breast cancer diagnosis ([table 1](#T1){ref-type="table"}). The patients were equally distributed across age categories. Breast cancer stage was localised in 58% of the patients, and 60% were oestrogen receptor positive. The majority of patients had a low Charlson Comorbidity Index score (81%).

###### 

Characteristics of patients with breast cancer, Denmark, 1990--2017

  Total                                                   84 972 (100)
  ------------------------------------------------------- -------------------
  Median follow-up time, years (25th--75th percentiles)   7.4 (3.5--12.9)
  Median age, years (25th--75th percentiles)              61.3 (51.7--70.0)
  Age group                                               
   18--49 years                                           17 220 (20.3)
   50--59 years                                           22 107 (26.0)
   60--69 years                                           24 535 (28.9)
   ≥70 years                                              21 110 (24.8)
  Calendar period                                         
   1990--2006                                             46 889 (55.2)
   2007--2017                                             38 083 (44.8)
  Breast cancer stage                                     
   Localised                                              48 960 (57.6)
   Regional spread                                        36 012 (42.4)
  Oestrogen receptor status\*                             
   Positive                                               42 192 (59.8)
   Negative                                               9705 (13.8)
   Unknown                                                18 612 (26.4)
  *HER2* receptor status\*                                
   Positive                                               1944 (2.8)
   Negative                                               11 711 (16.6)
   Unknown                                                56 854 (80.6)
  Treatment within the first year after diagnosis         
   Radiotherapy                                           43 722 (51.5)
   Chemotherapy                                           27 117 (31.9)
   Tamoxifen therapy                                      14 789 (17.4)
   Aromatase inhibitor treatment†                         594 (1.6)
   Lumpectomy\*                                           40 833 (57.9)
   Mastectomy\*                                           32 229 (45.7)
  Charlson Comorbidity Index score                        
   Low (score=0)                                          68 812 (81.0)
   Moderate (score=1--2)                                  14 317 (16.9)
   Severe (score \>2)                                     1843 (2.2)

Data are numbers (%) unless otherwise specified.

\*Restricted to 1996 onwards due to limitations in data availability.

†Restricted to 2007 onwards due to limited registration.

*HER2*, human epidermal growth factor receptor 2.

During the 28 years of follow-up (median, 7.4 years), 2340 incident gastrointestinal cancers were diagnosed among patients with breast cancer. The cumulative incidence of gastrointestinal cancers after 1 and 20 years of follow-up was 0.26% and 4.40% (0.01% and 0.18% for oesophagus cancer, 0.02% and 0.31% for stomach cancer, 0.01% and 0.07% for small intestine cancer, 0.13% and 2.15% for colon cancer, 0.03% and 0.72% for rectum cancer, 0.01% and 0.08% for anal canal cancer, 0.00% and 0.10% for liver cancer, 0.01% and 0.14% for gallbladder and biliary tract cancer, and 0.03% and 0.65% for pancreas cancer; [figure 1](#F1){ref-type="fig"}). The incidence rate per 100 000 person years was increasing slightly during follow-up for any gastrointestinal cancers (319 during +1 years, 249 during 2--5 years, 336 during 6--10 years, and 398 beyond 10 years of follow-up; [table 2](#T2){ref-type="table"}). The SIR for cancer of the stomach was increased approximately 1.5-fold during 2--5 year of follow-up (1.48, 95% CI 1.13 to 1.90) and 6--10 years of follow-up (1.43, 95% CI 1.06 to 1.88), after which it was moderately elevated at 1.2-fold. The SIR for cancer of the colon was neutral during 2--5 years of follow-up, and approximately 1.2-fold increased beyond 5 years of follow-up ([table 2](#T2){ref-type="table"}). The excess risk of colon cancer was mainly driven by localised cancer (+1 year SIR estimates were 1.20, 95% CI 1.09 to 1.33 for localised colon cancer, 1.08, 95% CI 0.94 to 1.23 for regional spread disease, and 1.06, 95% CI 0.93 to 1.21 for distant stage cancer). For cancer of the oesophagus, the SIR was increased only during 6--10 years (1.55, 95% CI 1.10 to 2.13). While there was a weak association with pancreas cancer beyond 10 years after breast cancer diagnosis, the risks of the remaining gastrointestinal cancers were not appreciably increased at any point during follow-up.

![Cumulative incidence of gastrointestinal cancers after a breast cancer diagnosis during 20 years of follow-up.](bmjgast-2020-000413f01){#F1}

###### 

Risk of selected site-specific gastrointestinal cancers in patients with breast cancer (1990--2017), by follow-up periods

                                     +1 year\*   2--5 years         6--10 years           +10 years                                                                                                                            
  ---------------------------------- ----------- ------------------ --------------------- ----------- ------------------ --------------------- --------- ------------------ --------------------- --------- ------------------ ---------------------
  Gastrointestinal cancers overall   2124/1931   319 (305 to 332)   1.10 (1.05 to 1.15)   667/660     249 (230 to 268)   1.01 (0.94 to 1.09)   709/605   336 (312 to 361)   1.17 (1.09 to 1.26)   748/666   398 (369 to 426)   1.12 (1.04 to 1.21)
  Upper gastrointestinal cancers     279/222     42 (37 to 47)      1.26 (1.11 to 1.41)   89/78       33 (26 to 40)      1.14 (0.92 to 1.41)   101/70    48 (39 to 57)      1.45 (1.18 to 1.76)   89/75     47 (37 to 57)      1.19 (0.96 to 1.47)
   Oesophagus                        83/77       12 (10 to 15)      1.07 (0.86 to 1.33)   17/26       6 (3 to 9)         0.64 (0.37 to 1.03)   38/24     18 (12 to 24)      1.55 (1.10 to 2.13)   28/26     15 (9 to 20)       1.06 (0.70 to 1.53)
   Stomach                           157/115     24 (20 to 27)      1.37 (1.16 to 1.60)   61/41       23 (17 to 29)      1.48 (1.13 to 1.90)   51/36     24 (18 to 31)      1.43 (1.06 to 1.88)   45/38     24 (17 to 31)      1.19 (0.87 to 1.60)
   Small intestine                   39/30       6 (4 to 8)         1.29 (0.92 to 1.76)   11/10       4 (2 to 7)         1.09 (0.54 to 1.94)   12/9      6 (2 to 9)         1.26 (0.65 to 2.21)   16/11     9 (4 to 13)        1.50 (0.86 to 2.44)
  Lower gastrointestinal cancers     1429/1301   214 (203 to 226)   1.10 (1.04 to 1.16)   453/442     169 (154 to 185)   1.03 (0.93 to 1.12)   476/407   226 (206 to 246)   1.17 (1.07 to 1.28)   500/452   266 (242 to 289)   1.11 (1.01 to 1.21)
   Colon incl. rectosigmoid colon    1028/916    154 (145 to 164)   1.12 (1.06 to 1.19)   314/307     117 (104 to 130)   1.02 (0.91 to 1.14)   342/286   162 (145 to 179)   1.20 (1.07 to 1.33)   372/323   198 (178 to 218)   1.15 (1.04 to 1.28)
   Rectum                            362/343     54 (49 to 60)      1.06 (0.95 to 1.17)   128/120     48 (40 to 56)      1.07 (0.89 to 1.27)   121/108   57 (47 to 68)      1.12 (0.93 to 1.34)   113/115   60 (49 to 71)      0.98 (0.81 to 1.18)
   Anal canal                        39/42       6 (4 to 8)         0.93 (0.66 to 1.27)   11/15       4 (2 to 7)         0.73 (0.36 to 1.31)   13/13     6 (3 to 10)        0.98 (0.52 to 1.67)   15/14     8 (4 to 12)        1.11 (0.62 to 1.83)
  Other gastrointestinal cancers     416/408     62 (56 to 68)      1.02 (0.92 to 1.12)   125/140     47 (39 to 55)      0.89 (0.74 to 1.06)   132/128   63 (52 to 73)      1.03 (0.86 to 1.22)   159/140   84 (71 to 98)      1.13 (0.97 to 1.33)
   Liver                             47/64       7 (5 to 9)         0.73 (0.54 to 0.97)   13/22       5 (2 to 8)         0.58 (0.31 to 1.00)   19/20     9 (5 to 13)        0.95 (0.57 to 1.48)   15/22     8 (4 to 12)        0.69 (0.38 to 1.13)
   Gallbladder and biliary tract     65/68       10 (7 to 12)       0.96 (0.74 to 1.23)   20/24       7 (4 to 11)        0.85 (0.52 to 1.31)   16/21     8 (4 to 11)        0.76 (0.43 to 1.23)   29/23     15 (10 to 21)      1.26 (0.85 to 1.82)
   Pancreas                          304/277     46 (40 to 51)      1.10 (0.98 to 1.23)   92/94       34 (27 to 41)      0.97 (0.79 to 1.20)   97/87     46 (37 to 55)      1.12 (0.91 to 1.36)   115/95    61 (50 to 72)      1.21 (1.00 to 1.45)

\*Main analysis

E, expected; IR, incidence rate; O, observed; PY, person years; SIR, standardised incidence ratio.

Time-trend analyses revealed that the risk was higher than expected for lower gastrointestinal cancers, particularly colon cancer, but only after 2007 (SIR=1.21, 95% CI 1.09 to 1.34; [table 3](#T3){ref-type="table"}). The opposite trend was observed for upper gastrointestinal cancers, where the SIR was increased during the first part of the study (1.42, 95% CI 1.19 to 1.68). The remaining outcomes were largely unaffected by calendar period stratification.

###### 

Risk of selected site-specific gastrointestinal cancers in patients with breast cancer (1990--2017), by calendar periods

                                     1990--2006   2007--2017                                                            
  ---------------------------------- ------------ ------------------ --------------------- --------- ------------------ ---------------------
  Gastrointestinal cancers overall   864/814      270 (252 to 288)   1.06 (0.99 to 1.14)   512/451   323 (295 to 350)   1.13 (1.04 to 1.24)
  Upper gastrointestinal cancers     135/95       42 (35 to 49)      1.42 (1.19 to 1.68)   55/53     35 (25 to 44)      1.05 (0.79 to 1.36)
   Oesophagus                        39/32        12 (8 to 16)       1.21 (0.86 to 1.66)   16/19     10 (5 to 15)       0.85 (0.49 to 1.39)
   Stomach                           78/52        24 (19 to 30)      1.50 (1.19 to 1.87)   34/25     21 (14 to 29)      1.36 (0.94 to 1.90)
   Small intestine                   18/11        6 (3 to 8)         1.65 (0.98 to 2.60)   5/9       3 (0 to 6)         0.57 (0.19 to 1.34)
  Lower gastrointestinal cancers     558/543      175 (160 to 189)   1.03 (0.94 to 1.12)   371/306   234 (210 to 257)   1.21 (1.09 to 1.34)
   Colon incl. rectosigmoid colon    378/379      118 (106 to 130)   1.00 (0.90 to 1.10)   278/215   175 (155 to 196)   1.30 (1.15 to 1.46)
   Rectum                            162/148      51 (43 to 59)      1.10 (0.94 to 1.28)   87/80     55 (43 to 66)      1.09 (0.87 to 1.34)
   Anal canal                        18/17        6 (3 to 8)         1.06 (0.63 to 1.68)   6/11      4 (1 to 7)         0.53 (0.19 to 1.15)
  Other gastrointestinal cancers     171/175      54 (45 to 62)      0.97 (0.83 to 1.13)   86/93     54 (43 to 66)      0.93 (0.74 to 1.15)
   Liver                             22/27        7 (4 to 10)        0.82 (0.51 to 1.24)   10/16     6 (2 to 10)        0.64 (0.31 to 1.19)
   Gallbladder and biliary tract     23/30        7 (4 to 10)        0.77 (0.49 to 1.16)   13/15     8 (4 to 13)        0.87 (0.46 to 1.49)
   Pancreas                          126/119      39 (33 to 46)      1.06 (0.88 to 1.26)   63/62     40 (30 to 49)      1.01 (0.78 to 1.29)

The analysis was restricted to 1--10 years of follow-up.

E, expected; IR, incidence rate; O, observed; PY, person years; SIR, standardised incidence ratio.

Additional analyses {#s3-1}
-------------------

In age-stratified analyses, the association was attenuated with increasing age for all subtypes of gastrointestinal cancer ([table 4](#T4){ref-type="table"}). This pattern was especially pronounced for upper gastrointestinal cancers. No substantial difference in risk of secondary cancers was observed for localised and regional breast cancer stages with the exception of upper gastrointestinal cancers where the SIRs were 1.52 (95% CI 1.27 to 1.81) for regionally advanced breast cancer and 1.09 (95% CI 0.93 to 1.28) for localised breast cancer. When stratifying by oestrogen receptor status, the SIRs were not substantially affected for any outcome. The SIR of lower gastrointestinal cancers was elevated among *HER2* positive patients, but not substantially for *HER2* negative patients.

###### 

Risk of gastrointestinal cancers among 1-year patients with breast cancer, by subgroups

                                       Observed/expected   Incidence rate per 100 000 person years (95% CI)   Standardised incidence ratio (95% CI)
  ------------------------------------ ------------------- -------------------------------------------------- ---------------------------------------
  **Upper gastrointestinal cancers**                                                                          
  Age group                                                                                                   
   18--49 years                        40/23               23 (16 to 30)                                      1.72 (1.23 to 2.35)
   50--69 years                        164/136             43 (36 to 50)                                      1.21 (1.03 to 1.41)
   ≥70 years                           75/63               68 (53 to 84)                                      1.18 (0.93 to 1.48)
  Breast cancer stage                                                                                         
   Localised                           151/138             38 (32 to 44)                                      1.09 (0.93 to 1.28)
   Regional                            128/84              48 (40 to 56)                                      1.52 (1.27 to 1.81)
  Oestrogen receptor status\*                                                                                 
   Positive                            124/105             40 (33 to 47)                                      1.18 (0.98 to 1.40)
   Negative                            26/19               41 (25 to 56)                                      1.40 (0.91 to 2.05)
   Unknown                             50/39               42 (30 to 54)                                      1.28 (0.95 to 1.69)
  *HER2* status\*                                                                                             
   Positive                            5/2                 57 (7 to 106)                                      2.16 (0.70 to 5.04)
   Negative                            12/11               33 (15 to 52)                                      1.08 (0.56 to 1.89)
   Unknown                             183/150             41 (35 to 47)                                      1.22 (1.05 to 1.41)
  **Lower gastrointestinal cancers**                                                                          
  Age group                                                                                                   
   18--49 years                        149/119             85 (72 to 99)                                      1.25 (1.06 to 1.47)
   50--69 years                        861/777             225 (210 to 240)                                   1.11 (1.04 to 1.18)
   ≥70 years                           419/404             381 (344 to 417)                                   1.04 (0.94 to 1.14)
  Breast cancer stage                                                                                         
   Localised                           864/811             217 (202 to 231)                                   1.07 (1.00 to 1.14)
   Regional                            565/490             211 (194 to 229)                                   1.15 (1.06 to 1.25)
  Oestrogen receptor status\*                                                                                 
   Positive                            715/623             230 (213 to 247)                                   1.15 (1.06 to 1.23)
   Negative                            123/108             193 (159 to 227)                                   1.14 (0.95 to 1.36)
   Unknown                             243/229             204 (179 to 230)                                   1.06 (0.93 to 1.20)
  *HER2* status\*                                                                                             
   Positive                            22/13               249 (145 to 353)                                   1.68 (1.05 to 2.54)
   Negative                            76/64               212 (164 to 259)                                   1.19 (0.94 to 1.49)
   Unknown                             983/883             219 (205 to 233)                                   1.11 (1.04 to 1.18)
  **Other gastrointestinal cancers**                                                                          
  Age group                                                                                                   
   18--49 years                        46/35               26 (19 to 34)                                      1.32 (0.96 to 1.75)
   50--69 years                        252/249             66 (58 to 74)                                      1.01 (0.89 to 1.15)
   ≥70 years                           118/125             107 (88 to 127)                                    0.94 (0.78 to 1.13)
  Breast cancer stage                                                                                         
   Localised                           264/255             66 (58 to 74)                                      1.04 (0.92 to 1.17)
   Regional                            152/154             57 (48 to 66)                                      0.99 (0.84 to 1.16)
  Oestrogen receptor status\*                                                                                 
   Positive                            196/194             63 (54 to 72)                                      1.01 (0.87 to 1.16)
   Negative                            39/34               61 (42 to 80)                                      1.16 (0.83 to 1.59)
   Unknown                             66/72               56 (42 to 69)                                      0.92 (0.71 to 1.17)
  *HER2* status\*                                                                                             
   Positive                            †                   23 (0 to 54)                                       0.50 (0.06 to 1.81)
   Negative                            16/19               45 (23 to 66)                                      0.84 (0.48 to 1.36)
   Unknown                             †                   63 (56 to 70)                                      1.03 (0.91 to 1.15)

\*Restricted to 1996 onwards due to limitations in data availability.

†Observed and expected numbers are not reported due to too few events.

*HER2*, human epidermal growth factor receptor 2.

In analyses stratified by treatment during the first year after the breast cancer diagnosis, the SIR was largely unaffected by radiotherapy, chemotherapy, and tamoxifen therapy for all outcomes ([table 5](#T5){ref-type="table"}). We observed no impact of lumpectomy or mastectomy on the risk of secondary gastrointestinal cancers. Due to sparse data, estimates were inconclusive for patients receiving aromatase inhibitor treatment. The sensitivity analyses allowing a minimum of 2 years of follow-up revealed estimates consistent with the main analysis (data not shown).

###### 

Risk of gastrointestinal cancers in patients with breast cancer, by treatment during the first year after breast cancer diagnosis

                                    Observed/expected   Incidence rate per 100 000 person years (95% CI)   Standardised incidence ratio (95% CI)
  --------------------------------- ------------------- -------------------------------------------------- ---------------------------------------
  Upper gastrointestinal cancers                                                                           
  Radiotherapy                                                                                             
   No                               163/130             45 (38 to 52)                                      1.26 (1.07 to 1.47)
   Yes                              116/93              38 (31 to 45)                                      1.25 (1.03 to 1.50)
  Chemotherapy                                                                                             
   No                               221/184             46 (40 to 52)                                      1.20 (1.05 to 1.37)
   Yes                              58/39               31 (23 to 40)                                      1.51 (1.14 to 1.95)
  Tamoxifen therapy                                                                                        
   No                               224/180             41 (35 to 46)                                      1.24 (1.09 to 1.42)
   Yes                              55/42               47 (35 to 59)                                      1.30 (0.98 to 1.70)
  Aromatase inhibitor treatment\*                                                                          
   No                               †                   34 (25 to 43)                                      1.03 (0.78 to 1.35)
   Yes                              †                   131 (−50 to 312)                                   2.70 (0.33 to 9.74)
  Lumpectomy‡                                                                                              
   No                               96/74               46 (37 to 55)                                      1.30 (1.05 to 1.59)
   Yes                              104/89              37 (30 to 44)                                      1.16 (0.95 to 1.41)
  Mastectomy‡                                                                                              
   No                               84/79               34 (27 to 42)                                      1.07 (0.85 to 1.32)
   Yes                              116/84              47 (38 to 55)                                      1.38 (1.14 to 1.65)
  Lower gastrointestinal cancers                                                                           
  Radiotherapy                                                                                             
   No                               810/771             225 (210 to 241)                                   1.05 (0.98 to 1.13)
   Yes                              619/530             202 (186 to 217)                                   1.17 (1.08 to 1.26)
  Chemotherapy                                                                                             
   No                               1168/1092           242 (228 to 256)                                   1.07 (1.01 to 1.13)
   Yes                              261/208             141 (124 to 159)                                   1.25 (1.11 to 1.42)
  Tamoxifen therapy                                                                                        
   No                               1158/1049           211 (199 to 223)                                   1.10 (1.04 to 1.17)
   Yes                              271/251             231 (204 to 259)                                   1.08 (0.95 to 1.21)
  Aromatase inhibitor treatment\*                                                                          
   No                               †                   234 (210 to 258)                                   1.22 (1.10 to 1.35)
   Yes                              †                   196 (−26 to 418)                                   0.65 (0.13 to 1.88)
  Lumpectomy‡                                                                                              
   No                               499/443             237 (217 to 258)                                   1.13 (1.03 to 1.23)
   Yes                              582/517             205 (189 to 222)                                   1.13 (1.04 to 1.22)
  Mastectomy‡                                                                                              
   No                               507/456             207 (189 to 225)                                   1.11 (1.02 to 1.21)
   Yes                              574/504             231 (212 to 250)                                   1.14 (1.05 to 1.24)
  Other gastrointestinal cancers                                                                           
  Radiotherapy                                                                                             
   No                               263/243             73 (64 to 82)                                      1.08 (0.96 to 1.22)
   Yes                              153/165             50 (42 to 58)                                      0.92 (0.78 to 1.08)
  Chemotherapy                                                                                             
   No                               355/345             74 (66 to 81)                                      1.03 (0.92 to 1.14)
   Yes                              61/63               33 (25 to 41)                                      0.97 (0.74 to 1.24)
  Tamoxifen therapy                                                                                        
   No                               351/329             64 (57 to 71)                                      1.07 (0.96 to 1.19)
   Yes                              65/80               56 (42 to 69)                                      0.82 (0.63 to 1.04)
  Aromatase inhibitor treatment\*                                                                          
   No                               86/92               54 (43 to 66)                                      0.93 (0.75 to 1.15)
   Yes                              †                                                                      
  Lumpectomy‡                                                                                              
   No                               142/139             68 (56 to 79)                                      1.02 (0.86 to 1.21)
   Yes                              159/160             56 (47 to 65)                                      0.99 (0.84 to 1.16)
  Mastectomy‡                                                                                              
   No                               145/141             59 (50 to 69)                                      1.03 (0.87 to 1.21)
   Yes                              156/158             63 (53 to 73)                                      0.99 (0.84 to 1.16)

\*Restricted to 2007 onwards due to limitations in data availability.

†Observed and expected numbers are not reported due to too few events.

‡Restricted to 1996 onwards due to limitations in data availability.

Discussion {#s4}
==========

In this Danish population-based study, patients with breast cancer had slightly higher than expected long-term risk (\<10 years) of cancers of the oesophagus, stomach, and colon, but not other gastrointestinal cancers compared with risks in the general population. The associations were strongest for stomach cancer. Our analyses focusing on temporality showed that the risk of upper gastrointestinal cancer was only increased before 2007, while the risk of lower gastrointestinal cancer only was increased after 2007. The associations were generally stronger in younger versus elderly patients. No substantial treatment effects were observed for patients treated with radiotherapy, chemotherapy, tamoxifen, lumpectomy or mastectomy and there was no difference in subgroups of patients with oestrogen receptor positive breast cancer.

In the present study, we confirmed the findings of a previous study of 525 527 patients with breast cancer from 13 European countries, suggesting a higher than expected long-term (1--9 years) risk of new-onset oesophageal cancer (1.3--2.1-fold), stomach cancer (1.3--1.5-fold), and colorectal cancer (1.2--1.3 fold) among patients with breast cancer.[@R10] Further, our data largely confirmed the findings of a Dutch study of 58 068 patients with invasive breast cancer (1989--2003), which reported increased risks for oesophagus cancer (1.6-fold), stomach cancer (1.3-fold), colorectal cancers (1.1--1.3-fold), but not other gastrointestinal cancers (pancreas and gall bladder).[@R12] The same pattern for colorectal cancer and pancreas cancer was found in the European Prospective Investigation into Cancer and Nutrition cohort.[@R14] In contrast to our findings, two studies of 1-year breast cancer survivors recorded in the Danish Breast Cancer Cooperative Group (DBCG) during 1977--2001[@R11] did not report any substantial increased risk for oesophagus cancer, stomach cancer, colon cancer, or other types of gastrointestinal cancers. Other studies from Taiwan,[@R5] USA,[@R15] and France[@R8] reported data with no substantial association between breast cancer and gastrointestinal cancers overall.

Few studies examined the impact of various treatment modalities on the risk of gastrointestinal cancers following a breast cancer diagnosis, yielding somewhat conflicting results.[@R6] In many of these studies, relatively few gastrointestinal cancer outcomes occurred across the different exposure/treatment groups, resulting in imprecise effect estimates and thus difficulties in drawing meaningful conclusions. Based on data from the Osaka Cancer Registry in Japan (1973--2003),[@R13] recent data from the DBCG,[@R6] and our study, radiation therapy was linked to an increased risk of mainly stomach cancer. A Japanese study found increased risk of stomach cancer among tamoxifen-treated patients, but not among non-tamoxifen-treated patients---a finding which could not be confirmed in our analysis. Studies on chemotherapy and subsequent risk of gastrointestinal cancers are sparse, heterogeneous and not directly comparable to our findings.

The mechanisms by which breast cancer are associated with some but not all gastrointestinal cancers are probably complex and multifactorial. Cancers potentially attributable to local radiotherapy for breast cancer include oesophagus and stomach cancer due to the close proximity to the breasts. Radiation therapy has become increasingly targeted during the past decades, and thus less likely to affect tissues surrounding the breast. This may explain why the associations observed in our study tapered off in the last part of the study period, in contrast to previous studies.[@R10] In Denmark, the national breast cancer screening programme was launched in 2007. Consequently, a larger proportion of women diagnosed in the late study period rather than the early study period likely were patients with localised disease. These patients require less extensive cancer treatment, and this mechanism may contribute to our findings.

It is also possible that breast cancer and some gastrointestinal cancers are independent cancers driven by shared genetic mutations, but with a longer latency period for gastrointestinal cancers. For example, *HER2* overexpression is increasingly recognised as a molecular abnormality involved in the pathogenesis of gastric and oesophageal cancers.[@R29] Similarly, a recent study of patients with Lynch syndrome reported a markedly higher risk of breast cancer among *MSH2* mutation carriers than in the general Canadian population, suggesting a link between colorectal cancer and breast cancer.[@R30] Beyond breast and ovarian cancers, it has previously been proposed that mutations in the *BRCA1* and *BRCA2* genes increase risks for pancreatic cancer. This potential association was not apparent in other studies,[@R10] but cannot be ruled out based on our observations. In addition, clear patterns have emerged that alcohol consumption is linked to both breast cancer and many other types of cancer, including gastrointestinal cancers.[@R31] As opposed to this, use of non-steroidal anti-inflammatory drugs, which is commonly used among patients with breast cancer, may have reduced the risk of some new primary gastrointestinal cancers, for example, colorectal cancer.[@R32] Importantly, we showed that the SIR was moderately increased for colon cancer after 2007. A national population-based screening programme for colon cancer was implemented in Denmark in 2014. This could have affected our estimates if breast cancer survivors were more likely to participate in the screening programmes and opportunistic screening than individuals in the general population. Oestrogen pathways may be involved in the development of colon cancer,[@R33] and therefore the introduction of aromatase inhibitors may, at least partly, contribute to our findings, although a recent study did not report an association between use of aromatase inhibitors and colon cancer.[@R34]

Knowing and quantifying the risk of gastrointestinal cancers among patients with breast cancer are of major public interest to substantiate and possibly refine guideline recommendations. Although our analysis suggested slightly elevated SIR estimates, the cumulative risk of cancer was relatively low, with highest risk observed for colon cancer. It was not an objective of our study to determine whether patients with breast cancer would benefit from additional screening, for example, colonoscopy, but the low absolute risks support that extensive screening strategies to detect more gastrointestinal cancers are not indicated.

Our analysis was based on detailed population-based data with long-term complete follow-up in a uniform healthcare system. Thus, our results are less prone to selection bias, stemming from inclusion of specific study participants or informative loss to follow-up. Limitations should also be addressed. The relatively low number of rare gastrointestinal cancer events prohibits drawing firm conclusions in some of the subgroup analyses. Although we had several detailed clinical data, we had some missing data issues (eg, *HER2* status) and lacked data on some variables (eg, life style factors). The accuracy and completeness of cancer diagnoses are high in the DCR,[@R18] although the breast cancer diagnosis has not been validated.

Conclusion {#s5}
==========

In this study, the risk of being diagnosed with oesophagus cancer, stomach cancer, and colon cancer, but not other gastrointestinal cancers, was higher for patients with breast cancer than for the general population. The excess risk was most noteworthy for stomach cancer. Underlying explanations for these observations may include shared risk factors, surveillance and/or be related to cancer treatments. The risk of lower gastrointestinal cancers was negligible before 2007, but increased thereafter. For upper gastrointestinal cancers, the opposite pattern was observed.
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